4 Stocks to Watch on Monday: Micron, Mundy, AMC, ELF
ByAinvest
Monday, Aug 11, 2025 9:08 am ET1min read
AMC--
Micron also raised its non-GAAP gross margin guidance to 44.0% to 45.0%, up from its earlier projection of 41.0% to 43.0%. Additionally, the company increased its non-GAAP earnings per share (EPS) forecast to $2.78 to $2.92, up from $2.35 to $2.65, and above the consensus estimate of $2.52. The company attributed the improved outlook to better pricing conditions, particularly in DRAM products, and strong execution across its operations [1].
Micron Executive Vice President and Chief Business Officer, Sumit Sadana, will provide further details during a fireside chat at the 2025 Keybanc Technology Conference in Park City, Utah, later today.
Investors should also keep an eye on other key stocks. Moderna (MNDY) has seen fluctuations in its stock price due to ongoing developments in its COVID-19 vaccine. AMC Entertainment (AMC) continues to attract attention as the company navigates the challenges of the movie theater industry. Elanco Animal Health (ELAN) reported strong Q2 2025 results, with 5% year-over-year revenue growth and a significant increase in innovation revenue, positioning it for continued growth [2, 3].
As the market awaits key inflation reports, investors are closely monitoring the economic indicators that could impact stock performance. Micron's positive guidance and Elanco's strong performance provide a positive outlook for these companies, but the broader market sentiment remains influenced by macroeconomic factors.
References:
[1] https://uk.finance.yahoo.com/news/micron-stock-rises-boosting-guidance-124810300.html
[2] https://www.ainvest.com/news/micron-technology-stock-grown-10-years-2508/
[3] https://www.ainvest.com/news/elanco-animal-health-q2-2025-innovation-driven-growth-accelerated-deleveraging-justify-buy-rating-2508/
ELAN--
MNDY--
MRNA--
MU--
Micron Technology (MU) stock rose on Monday, while investors await key inflation reports. Other stocks to watch include Moderna (MNDY), AMC Entertainment (AMC), and Elanco Animal Health (ELF).
Micron Technology (MU) stock surged 5.6% in pre-market trading on Monday, driven by the company's positive fourth-quarter fiscal 2025 guidance. The Boise, Idaho-based memory chipmaker revised its revenue forecast to $11.1 to $11.3 billion, an increase from its previous guidance of $10.4 to $11.0 billion. This new outlook exceeds analysts' consensus estimates of $10.74 billion [1].Micron also raised its non-GAAP gross margin guidance to 44.0% to 45.0%, up from its earlier projection of 41.0% to 43.0%. Additionally, the company increased its non-GAAP earnings per share (EPS) forecast to $2.78 to $2.92, up from $2.35 to $2.65, and above the consensus estimate of $2.52. The company attributed the improved outlook to better pricing conditions, particularly in DRAM products, and strong execution across its operations [1].
Micron Executive Vice President and Chief Business Officer, Sumit Sadana, will provide further details during a fireside chat at the 2025 Keybanc Technology Conference in Park City, Utah, later today.
Investors should also keep an eye on other key stocks. Moderna (MNDY) has seen fluctuations in its stock price due to ongoing developments in its COVID-19 vaccine. AMC Entertainment (AMC) continues to attract attention as the company navigates the challenges of the movie theater industry. Elanco Animal Health (ELAN) reported strong Q2 2025 results, with 5% year-over-year revenue growth and a significant increase in innovation revenue, positioning it for continued growth [2, 3].
As the market awaits key inflation reports, investors are closely monitoring the economic indicators that could impact stock performance. Micron's positive guidance and Elanco's strong performance provide a positive outlook for these companies, but the broader market sentiment remains influenced by macroeconomic factors.
References:
[1] https://uk.finance.yahoo.com/news/micron-stock-rises-boosting-guidance-124810300.html
[2] https://www.ainvest.com/news/micron-technology-stock-grown-10-years-2508/
[3] https://www.ainvest.com/news/elanco-animal-health-q2-2025-innovation-driven-growth-accelerated-deleveraging-justify-buy-rating-2508/

Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet